MarketCap
Facebook
X
Telegram
Country |
 Israel |
IPO year |
2019 |
Industry |
Biotechnology |
Stock Exchange |
NYSE AMERICAN |
Shares |
1.63 M |
Market Cap[1] |
$ 3.02 M |
EBITDA (LTM) |
$ -38.5 M |
P/E (LTM) |
0.00676 |
P/S (LTM) |
- |
EPS (LTM) |
22.19 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Chiasma, Inc.
CHMA
|
- | -6.00 % | $ 238 M | Nasdaq Global Select Market |  USA |
 |
Wave Life Sciences Ltd.
WVE
|
$ 3.2 | -11.19 % | $ 540 M | Nasdaq Global Select Market |  Singapore |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
- | - | $ 376 M | Nasdaq Global Market | USA |
 |
Cellect Biotechnology Ltd.
APOP
|
- | 0.38 % | $ 12.9 M | Nasdaq Global Select Market | Israel |
 |
AzurRx BioPharma, Inc.
AZRX
|
- | 2.07 % | $ 34.4 M | Nasdaq Capital Market | USA |
 |
Cerecor Inc.
CERC
|
- | -1.68 % | $ 283 M | Nasdaq Capital Market | USA |
 |
Constellation Pharmaceuticals, Inc.
CNST
|
- | - | $ 1.63 B | Nasdaq Global Select Market | USA |
 |
Auris Medical Holding Ltd.
EARS
|
- | -1.77 % | $ 39.2 M | Nasdaq Capital Market |  Bermuda |
 |
Dicerna Pharmaceuticals, Inc.
DRNA
|
- | 0.34 % | $ 2.98 B | Nasdaq Global Select Market,SPB | USA |
 |
ERYTECH Pharma S.A.
ERYP
|
- | 1.3 % | $ 27.7 M | Nasdaq Global Select Market |  France |
 |
22nd Century Group
XXII
|
$ 1.89 | -22.41 % | $ 348 K | NYSE American | USA |
 |
GW Pharmaceuticals plc
GWPH
|
- | - | $ 6.81 B | Nasdaq Global Select Market |  Britain |
 |
Kadmon Holdings, Inc.
KDMN
|
- | - | $ 1.7 B | Nasdaq Global Select Market | USA |
 |
Liminal BioSciences
LMNL
|
- | - | $ 256 M | Nasdaq Global Market |  Canada |
 |
argenx SE
ARGX
|
$ 894.61 | -3.95 % | $ 54.8 B | Nasdaq Global Select Market |  Niderland |
|
XBiotech
XBIT
|
$ 1.89 | -3.08 % | $ 57.6 M | Nasdaq Global Select Market | USA |
 |
Neos Therapeutics, Inc.
NEOS
|
- | -2.54 % | $ 57.2 M | Nasdaq Global Market | USA |
 |
Odonate Therapeutics, Inc.
ODT
|
- | -3.18 % | $ 58.5 M | Nasdaq Global Select Market | USA |
 |
Orphazyme A/S
ORPH
|
- | -2.25 % | $ 31.3 M | Nasdaq Global Select Market |  Danmark |
 |
Osmotica Pharmaceuticals plc
OSMT
|
- | -10.74 % | $ 89.9 M | Nasdaq Global Select Market | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
- | - | $ 1.77 B | Nasdaq Global Select Market | USA |
 |
Xenetic Biosciences
XBIO
|
$ 1.89 | -5.97 % | $ 3.22 M | Nasdaq Capital Market | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
$ 542.93 | -1.11 % | $ 139 B | Nasdaq Global Select Market,SPB | USA |
 |
Translate Bio, Inc.
TBIO
|
- | - | $ 2.81 B | Nasdaq Global Select Market,SPB | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
- | - | $ 1.94 B | Nasdaq Capital Market | Canada |
 |
Exicure
XCUR
|
$ 0.89 | -10.34 % | $ 5.6 M | Nasdaq Capital Market | USA |
 |
Urovant Sciences Ltd.
UROV
|
- | - | $ 532 M | Nasdaq Global Select Market | Britain |
 |
Acceleron Pharma Inc.
XLRN
|
- | - | $ 10.9 B | Nasdaq Global Market,SPB | USA |
 |
Zealand Pharma A/S
ZEAL
|
- | 0.52 % | $ 821 M | Nasdaq Global Select Market | Danmark |
 |
Zogenix, Inc.
ZGNX
|
- | -4.97 % | $ 664 M | Nasdaq Global Market,SPB | USA |
|
Yunhong International
ZGYH
|
- | 0.10 % | $ 92.2 M | Nasdaq Capital Market |  China |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
- | -7.58 % | $ 264 M | Nasdaq Global Select Market | USA |
 |
Xenon Pharmaceuticals
XENE
|
$ 37.65 | -3.93 % | $ 2.98 B | Nasdaq Global Select Market | Canada |
 |
Leap Therapeutics
LPTX
|
- | 368.57 % | $ 41.9 M | Nasdaq Global Market | USA |
 |
Zymeworks
ZYME
|
$ 28.83 | -6.82 % | $ 1.49 B | NYSE | Canada |
 |
Adial Pharmaceuticals
ADIL
|
$ 3.15 | -35.42 % | $ 2.11 M | Nasdaq Capital Market | USA |
 |
ADMA Biologics
ADMA
|
$ 13.2 | 25.91 % | $ 3.15 B | Nasdaq Global Market | USA |
 |
Cortexyme
CRTX
|
- | -1.05 % | $ 67.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Burford Capital Limited
BUR
|
$ 3.94 | -5.52 % | $ 863 M | NYSE | Britain |
 |
Daré Bioscience
DARE
|
$ 0.62 | -3.5 % | $ 6.93 M | Nasdaq Capital Market | USA |
 |
Fate Therapeutics
FATE
|
$ 1.86 | -11.24 % | $ 221 M | Nasdaq Global Market,SPB | USA |
 |
Greenwich LifeSciences
GLSI
|
$ 14.63 | -10.55 % | $ 198 M | Nasdaq Capital Market | USA |
 |
Halozyme Therapeutics
HALO
|
$ 123.1 | -5.55 % | $ 14.8 B | Nasdaq Global Select Market,SPB | USA |
 |
Hutchison China MediTech Limited
HCM
|
$ 14.15 | 1.65 % | $ 12.1 B | Nasdaq Global Select Market | China |
 |
Aptorum Group Limited
APM
|
- | - | $ 5.72 M | Nasdaq Global Select Market | China |
 |
iBio
IBIO
|
$ 0.73 | -8.74 % | $ 76 M | NYSE American | USA |
 |
Kodiak Sciences
KOD
|
$ 90.95 | -7.67 % | $ 4.84 B | Nasdaq Global Market,SPB | USA |
 |
Karyopharm Therapeutics
KPTI
|
$ 0.06 | -15.5 % | $ 656 | Nasdaq Global Select Market | USA |
 |
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Nasdaq Capital Market | Canada |
 |
BioAtla
BCAB
|
$ 1.74 | 0.64 % | $ 102 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.